RE: After a replay of the presentation22 Jun 2022 08:49
Michael... a very sober assessment.
It is astonishing to me that a company conducting trials which are showing clinical benefit to people on their death beds is going through a financial uncertainly like this.
Having dilution as an option (,even at 100%) is necessary in my opinion, always said that, and we need to ensure company keeps the lights on... once that is secured we need changes on the BoD (even at the highest level) . Or Duncan should not be the face of 4D any longer. Also, company's inability to attract IIs, considering the clinical trials successes, is legendary in my opinion - someone is required there to produce results, to deliver.
But for the time being i feel we need to put the anger aside and look at this company's pipeline value, what they have achieved and believe that big pharma will not just sit idle if trials are continuing to deliver good results (big pharma are also desperate for M&As and new licensing agreements for their pipelines, they wouldn't be just doing 4D a favour)
As an investor I am holding for now, but yesterday was a painful experience and I am now assessing my position daily. What hasn't changed is that one positive news re finances would catapult the SP very quickly.
Good luck to all of us still in the breach.